News

In this newly-created position, Dr Rossetti will have overall responsibility for scientific direction across the drug discovery and development process for Merck’s key therapeutic areas of diabetes and

The company is currently applying the long-acting delivery (LAD) technology to investigational drug candidates for the treatment of Parkinson’s disease and schizophrenia. The LAD technology is designed to

The active ingredient contained within Bema LA met the company’s expectations in terms of the amount absorbed into the bloodstream. Plasma concentrations (amount of active ingredient in the

The recommendation came following a meeting of the independent data safety monitoring board (DSMB). This was the fifth of several regularly scheduled reviews by the DSMB that will

The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ALS 2-0426. Designed in two parts, the initial double-blind, placebo controlled phase I clinical study will enroll

The data, which were presented at the recent Internationals AIDS Conference, were the final 48 week analysis of a phase IIb dose-finding study in HIV-1 infected adult patients

Abbott acquired the product through the acquisition of Knoll AG in 2002 before out-licensing it to Speedel in 2003. Based on the promising results from the phase II

Evotec has granted Takeda exclusive rights to a novel target in Alzheimer’s disease based on successful target identification and validation work triggering a milestone payment of over one

As part of the reorganization, David Shedlarz, vice chairman, will become principle deputy to Mr Kindler with expanded responsibilities including Pfizer global manufacturing, and worldwide strategic planning, licensing